| Literature DB >> 2943814 |
B A Zajac, D J West, W J McAleer, E M Scolnick.
Abstract
The Merck, Sharp and Dohme hepatitis B vaccine formulated from HBsAg produced by a recombinant strain of Saccharomyces cerevisiae has proven to be highly immunogenic and safe. A 10 micrograms dose of the vaccine produced an anti-HBs response of greater than or equal to 10 IU/l in 91% or more of healthy adults who completed the three-dose regimen. Children responded well to all levels of vaccine antigen utilised but developed maximum anti-HBs titres with 5 micrograms doses. The age of the vaccine recipient affected responsiveness. Younger adults (20-29 years) responded more rapidly and with higher anti-HBs titres than did older adults (greater than or equal to 50 years). Children responded faster and with higher anti-HBs levels than younger adults. Clinical reactions reported after vaccination were mild and transient.Entities:
Mesh：
Substances：
Year: 1986 PMID： 2943814 DOI： 10.1016/s0163-4453(86)92668-x
Source DB: PubMed Journal: J Infect ISSN： 0163-4453 Impact factor: 6.072